Sign in
Taking people in United StatesNo phase

Compares two treatments for nerve pain and numbness in type 2 diabetes

Compares a non-invasive nerve therapy with standard physical therapy in adults with diabetic nerve damage.

Key facts

Who runs it
Loma Linda University
Where
Loma Linda, United StatesSee the site
Trial code
Registry title
A Physiologic Comparison of Two Approaches to Treating Peripheral Neuropathy
Status
Recruiting
People taking part
40 people, planned
Started
8 Jan 2024
Expected to end
1 Aug 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Intraneural Facilitation Therapy Treatment
  • Standard Physical Therapy Treatment
Record updated
19 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 45 to 85 with moderate to severe nerve damage from type 2 diabetes. It compares two non-invasive treatments: INF® Therapy and standard physical therapy.

Age
45 to 85 years
Sex
All sexes can join.
Disease stage
Moderate to severe type 2 diabetic neuropathy, confirmed by a physician, with at least one symptom: numbness, tingling, burning, sharp pain or increased sensitivity.

Main reasons for not taking part

  • Other types of neuropathy not caused by diabetes, such as B12 deficiency or Charcot Marie Tooth
  • Chemotherapy or radiation
  • Lower leg or foot amputation, or open wounds
  • Pregnancy, taking beta blockers, or having a pacemaker
  • Smoking or ingesting marijuana, or active drug or alcohol misuse

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Between the ages of 45 and 85
  • Moderate to severe type II diabetic neuropathy with one or more symptoms including: numbness, tingling, burning, sharp pain, and/or increased sensitivity
  • Diagnosis confirmed by a physician
  • Cellphone access with Android 5.0 and up or iOS 14.0 or later

Who cannot take part

  • Chemotherapy
  • Radiation
  • Documented active drug and or alcohol misuse
  • Subjects with a medical condition predisposing them to medical decline during the next 6 months will be excluded from the study. Examples include:
  • Chronic liver disease
  • Other types of neuropathies not associated with diabetes including B12 deficiency and Charcot Marie Tooth
  • Allergies to cobalt, chrome, or nickel
  • Lower extremity amputations
  • Open wounds
  • Active inflammations
  • Morbid obesity
  • Pregnancy
  • Taking beta blockers
  • Unable to maintain steady fingers or operate a cellphone
  • Smoking or ingesting marijuana
  • Having a pacemaker

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 45 and 85 years old?

Where in United States

  • Loma Linda University Health Neuropathic Therapy CenterLoma Linda, United StatesContact: Mark Bussell, DPT, OCSTaking people

About the trial

What the trial wants to find out

Diabetic peripheral neuropathy is one of the most common and costly microvascular complications of diabetes impacting more than 50% of patients and costing more than 10.1 billion dollars annually. Intraneural Facilitation Therapy (INF® Therapy) is a non-invasive technique that has shown to improve balance and pain in patients with Type 2 Diabetic Peripheral Neuropathy (T2DPN); however, the underlying physiological mechanisms need further understanding. The purpose of this study is to investigate the physiological mechanisms behind two approaches to treating T2DPN, INF® Therapy and standard physical therapy. Eligible subjects presenting with diabetic neuropathy symptoms will be recruited and referred to the Loma Linda University Health's Neuropathic Therapy Center. Forty patients will be evenly randomized into two groups: an INF® Therapy Treatment group and standard physical therapy treatment group. Subjects will participate in 11 study visits over a period of 6 weeks. Non-invasive assessments will measure neuropathy pain, heart rate variability, neuropathy severity, blood oxygen levels, and blood flow under the skin. Lab draws will measure inflammation levels in the blood and how well blood sugar levels have been maintained over a period of about 3 months. Descriptive statistics and repeated measures ANOVA will be used to analyze data and answer the research questions. The findings of this study will provide a better understanding of how INF® Therapy and standard physical therapy work, subsequently improving non-invasive treatment methods for T2DPN patients.

The 2 groups in the trial

  • Intraneural Facilitation Therapy Treatment GroupTreatment being tested

    Subjects will receive nine 60-minute INF® Therapy Treatments during sessions 2 through 10. INF® Therapy is a non-invasive treatment that helps eliminate pain, tingling, numbness, and other symptoms that come with neuropathy.

    Treatment: Intraneural Facilitation Therapy Treatment

  • Standard Physical Therapy Treatment GroupTreatment being tested

    Subjects will receive nine 60-minute standard physical therapy treatments during sessions 2 through 10.

    Treatment: Standard Physical Therapy Treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Physiologic Comparison of Two Approaches to Treating Peripheral Neuropathy
Plain-language title
Compares two treatments for nerve pain and numbness in type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05577390, who can take part
Record updated
19 November 2025